EGFR DEGRADATION AGENT - BEIJING TIDE PHARMACEUTICAL CO LTD

Title:

EGFR DEGRADATION AGENT

Document Type and Number:

WIPO Patent Application WO/2023/198180

Kind Code:

A1

Abstract:

The present invention relates to a novel compound of general formula (A) capable of inhibiting and inducing degradation of EGFR, and a pharmaceutical composition comprising the compound, which can be used for treating diseases associated with EGFR kinase, such as cancer. The present invention further relates to preparation and use of the compound described above.

More Like This:

JP2005520782	Amide-containing compounds with improved water solubility and methods for improving the water solubility of amide-containing compounds
WO/1998/020013	NEW KNOEVENAGEL CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION AND THEIR USE
JP2526059	[Title of Invention] Anti-ulcer agent

Inventors:

WANG HONGJUN (CN)
WANG YEMING (CN)
WANG XIAOQIAN (CN)
ZHAO YANPING (CN)

Application Number:

PCT/CN2023/088336

Publication Date:

October 19, 2023

Filing Date:

April 14, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BEIJING TIDE PHARMACEUTICAL CO LTD (CN)

International Classes:

C07F9/6558; A61K31/675; A61P35/00; C07D401/14; C07D417/14

Domestic Patent References:

WO2021036922A1	2021-03-04
WO2022268229A1	2022-12-29
WO2022055181A1	2022-03-17

Foreign References:

CN114805303A	2022-07-29
CN112079866A	2020-12-15

Attorney, Agent or Firm:

LIU , SHEN & ASSOCIATES (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: REFRIGERATION APPLIANCE HAVING ONE OR MORE COMBINED FEATURES FOR MAKING ICE CREAM

Next Patent: CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION